Inici › Càncer de pròstata › Ohio › Cleveland
Assaigs clínics de Càncer de pròstata a Cleveland, OH
34 estudis de Càncer de pròstata busquen participants en centres de Cleveland i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutantFase 1/2
- The Cleveland Clinic Taussig Cancer Center, Cleveland
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
ReclutantFase 3
- MetroHealth Medical Center, Cleveland
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ReclutantFase 1
- University Hospitals Cleveland Medical Center, Cleveland
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
ReclutantFase 2
- MetroHealth Medical Center, Cleveland
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
ReclutantFase 2
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Cente, Cleveland
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Reclutant
- University Hospitals Cleveland Medical Center, Cleveland
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
ReclutantFase 1
- University Hospitals Cleveland Medical Center, Cleveland
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
ReclutantFase 3
- University Hospitals Cleveland Medical Center ( Site 0043), Cleveland
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
ReclutantFase 1
- University Hospitals Cleveland Medical Center, Cleveland
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
ReclutantFase 3
- University Hospitals Cleveland Medical Center, Cleveland
- UH Minoff Health Center at Chagrin Highlands, Orange · a 12 mi
- University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor · a 22 mi
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
ReclutantFase 2
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
Investigation of Impact of AI on Prostate Cancer Workflow
Reclutant
- Cleveland Clinic Foundation, Cleveland
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Reclutant
- University Hospitals Cleveland, Cleveland
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
ReclutantFase 3
- Case Western Reserve University, Cleveland
- Louis Stokes Cleveland VA Medical Center, Cleveland
- MetroHealth Medical Center, Cleveland
- i 5 més
The Vanguard Study: Testing a New Way to Screen for Cancer
ReclutantVoluntaris sans benvinguts
- Louis Stokes Cleveland VA Medical Center, Cleveland
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
ReclutantFase 3
- Research Site, Cleveland
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
ReclutantFase 2
- University Hospitals Cleveland Medical Center, Cleveland
FOG-001 in Locally Advanced or Metastatic Solid Tumors
ReclutantFase 1/2
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Reclutant
- Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
ReclutantFase 3
- Case Western Reserve University, Cleveland
- MetroHealth Medical Center, Cleveland
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- i 5 més
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
ReclutantEstudi observacional
- Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company, Cleveland
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
ReclutantFase 1
- Cleveland Clinic Foundation, Cleveland
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
ReclutantFase 4
- Cleveland Clinic Foundation, Cleveland
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
ReclutantFase 1/2
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
ReclutantEstudi observacional
- University Hospitals Cleveland Medical Center, Cleveland
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
ReclutantFase 1
- Research Site, Cleveland
Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
Reclutant
- UH Cleveland Medical Center, Cleveland
Cleveland African American Prostate Cancer Project
ReclutantVoluntaris sans benvinguts
- Barbershops Local to Cleveland, Cleveland
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
ReclutantFase 2/3
- Louis Stokes VA Medical Center, Cleveland, OH, Cleveland
Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer
Reclutant
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
ReclutantEstudi observacionalVoluntaris sans benvinguts
- Cleveland Clinic, Cleveland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Mayfield Heights · a 12 mi
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
ReclutantFase 3
- MetroHealth Medical Center, Cleveland
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
ReclutantFase 1
- Exelixis Clinical Site #7, Cleveland
Assaigs de Càncer de pròstata en altres ciutats
- New York City, NY103 estudis
- Houston, TX76 estudis
- Los Angeles, CA61 estudis
- Boston, MA59 estudis
- St. Louis, MO46 estudis
- Chicago, IL45 estudis
- San Francisco, CA45 estudis
- Philadelphia, PA44 estudis
- Baltimore, MD43 estudis
- Nashville, TN42 estudis
- Seattle, WA42 estudis
- Washington, DC38 estudis
Altres estudis a Cleveland
- Càncer de pulmó de cèl·lules no petites43 estudis
- Càncer (tots els tipus)36 estudis
- Càncer de mama35 estudis
- Insuficiència cardíaca33 estudis
- Càncer metastàtic30 estudis
- Càncer d'ovari30 estudis
- Càncer de pulmó26 estudis
- Càncer colorrectal24 estudis
- Malaltia cardiovascular22 estudis
- Càncer d'endometri20 estudis
- Leucèmia mieloide aguda20 estudis
- Malaltia de Crohn19 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.